piwik-script

Intern
    Onkologische Forschung

    Molecular screening of pediatric kidney tumors

    Identification of driver mutations in childhood renal tumors (in collaboration with DKFZ, Heidelberg, and Wellcome Trust Sanger Institute, Hinxton, UK)

    Our goal is the identification of driver mutations and actionable or predictive biomarkers for pediatric renal tumors in the context of the SIOP Renal Tumor Study Group (RTSG). We characterize tumor cohorts from entities like blastemal-type Wilms tumor, anaplastic Wilms tumor, clear cell sarcoma of the kidney (CCSK), or congenital mesoblastic nephroma (CMN) from the German pediatric renal tumor biobank. Analyses include whole genome, exome, transcriptome or methylome studies. Diagnostic aberrations should be turned into routine assays for general testing of clinical samples. We closely interact with the clinical study center and reference pathology for integrated data analysis.

    Recent Publications

    Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanic G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O'Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol. 2016; 34:3195-3203.

    van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwangler R, Verschuur AC, Vujanic GM, Leuschner I, Brok J, Rube C, Smets AM, Janssens GO, Godzinski J, Ramirez-Villar GL, de Camargo B, Segers H, Collini P, Gessler M, Bergeron C, Spreafico F, Graf N, International Society of Paediatric Oncology - Renal Tumour Study Group. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14:743-752.

    Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O'Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer cell. 2015; 27:298-311.

    Wegert J, Vokuhl C, Ziegler B, Ernestus K, Leuschner I, Furtwangler R, Graf N, Gessler M. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia. J Pathol Clin Res. 2017; 3:234-248.

    CMN paper in press after embargo

    Kontakt

    Comprehensive Cancer Center Mainfranken
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin
    Campus Medizin